-
Molecules (Basel, Switzerland) Jan 2023The dramatic rise in cancer incidence, alongside treatment deficiencies, has elevated cancer to the second-leading cause of death globally. The increasing morbidity and... (Review)
Review
The dramatic rise in cancer incidence, alongside treatment deficiencies, has elevated cancer to the second-leading cause of death globally. The increasing morbidity and mortality of this disease can be traced back to a number of causes, including treatment-related side effects, drug resistance, inadequate curative treatment and tumor relapse. Recently, anti-cancer bioactive peptides (ACPs) have emerged as a potential therapeutic choice within the pharmaceutical arsenal due to their high penetration, specificity and fewer side effects. In this contribution, we present a general overview of the literature concerning the conformational structures, modes of action and membrane interaction mechanisms of ACPs, as well as provide recent examples of their successful employment as targeting ligands in cancer treatment. The use of ACPs as a diagnostic tool is summarized, and their advantages in these applications are highlighted. This review expounds on the main approaches for peptide synthesis along with their reconstruction and modification needed to enhance their therapeutic effect. Computational approaches that could predict therapeutic efficacy and suggest ACP candidates for experimental studies are discussed. Future research prospects in this rapidly expanding area are also offered.
Topics: Humans; Antineoplastic Agents; Neoplasms; Peptides
PubMed: 36770815
DOI: 10.3390/molecules28031148 -
PloS One 2018To review the scientific literature related to the safe handling of hazardous drugs (HDs). (Review)
Review
OBJECTIVE
To review the scientific literature related to the safe handling of hazardous drugs (HDs).
METHOD
Critical analysis of works retrieved from MEDLINE, the Cochrane Library, Scopus, CINHAL, Web of Science and LILACS using the terms "Hazardous Substances", "Antineoplastic Agents" and "Cytostatic Agents", applying "Humans" and "Guidelines" as filters. Date of search: January 2017.
RESULTS
In total, 1100 references were retrieved, and from those, 61 documents were selected based on the inclusion and exclusion criteria: 24 (39.3%) documents related to recommendations about HDs; 27 (44.3%) about antineoplastic agents, and 10 (33.3%) about other types of substances (monoclonal antibodies, gene medicine and other chemical and biological agents). In 14 (23.3%) guides, all the stages in the manipulation process involving a risk due to exposure were considered. Only one guide addressed all stages of the handling process of HDs (including stages with and without the risk of exposure). The most described stages were drug preparation (41 guides, 67.2%), staff training and/or patient education (38 guides, 62.3%), and administration (37 guides, 60.7%). No standardized informatics system was found that ensured quality management, traceability and minimization of the risks associated with these drugs.
CONCLUSIONS
Most of the analysed guidelines limit their recommendations to the manipulation of antineoplastics. The most frequently described activities were preparation, training, and administration. It would be convenient to apply ICTs (Information and Communications Technologies) to manage processes involving HDs in a more complete and simpler fashion.
Topics: Antineoplastic Agents; Education, Medical, Continuing; Humans; Medical Staff; Patient Education as Topic; Practice Guidelines as Topic
PubMed: 29750798
DOI: 10.1371/journal.pone.0197172 -
The Oncologist Aug 2015“Accelerated Approval” (AA) has addressed important unmet needs in oncology. However, it is only justified if the drug fills a serious gap because such approval...
“Accelerated Approval” (AA) has addressed important unmet needs in oncology. However, it is only justified if the drug fills a serious gap because such approval entails risk and leads to marketing based on incomplete information about toxicity, dose, and therapeutic potential. Furthermore, the policy of requiring companion diagnostics for AA of drugs that target specific mutations needs further discussion.
Topics: Antineoplastic Agents; Drug Discovery; Humans; Imidazoles; Pyridazines
PubMed: 26173838
DOI: 10.1634/theoncologist.2015-0253 -
Anesthesiology Jul 2013
Topics: Antineoplastic Agents; Child, Preschool; Humans; Neoplasms; Poetry as Topic
PubMed: 23360901
DOI: 10.1097/ALN.0b013e3182874854 -
Cancer Treatment and Research... 2021With the development of trastuzumab for metastatic breast cancer a new era began in cancer drug development. The drug-diagnostic codevelopment model with its clinical...
With the development of trastuzumab for metastatic breast cancer a new era began in cancer drug development. The drug-diagnostic codevelopment model with its clinical enrichment trial design has enabled development of target specific drugs for molecular defined subsets of patients. Since the simultaneous approval of trastuzumab and the HercepTest in 1998, the number of FDA-approved drug-companion diagnostic combinations within oncology and hematology have steadily increased. By June 2021, the number of drugs that have a companion diagnostic (CDx) linked to its use has reached 46. For these drugs, the CDx assays play an important role in defining the patient population likely to respond and without the assay they will often lose their value. This short article is based on an analysis of the FDA List of Cleared or Approved Companion Diagnostic Devices and relevant information in the Drugs@FDA, and will focus on the drug-CDx combinations, drug classes, clinical development, and the regulatory path and status.
Topics: Antineoplastic Agents; Humans; Medical Oncology; Neoplasms
PubMed: 34844911
DOI: 10.1016/j.ctarc.2021.100492 -
Toxins Jun 2020The level of complexity in a disease like cancer presents a number of challenges for effective treatment development, which require significant innovation to overcome...
The level of complexity in a disease like cancer presents a number of challenges for effective treatment development, which require significant innovation to overcome [...].
Topics: Animals; Antineoplastic Agents; History, 20th Century; History, 21st Century; Humans; Neoplasms; Toxins, Biological
PubMed: 32585926
DOI: 10.3390/toxins12060416 -
International Journal of Molecular... Nov 2023Cancer poses a significant global public health challenge [...].
Cancer poses a significant global public health challenge [...].
Topics: Humans; Antineoplastic Agents; Neoplasms
PubMed: 38003270
DOI: 10.3390/ijms242216066 -
International Journal of Molecular... Oct 2022Oncological diseases have currently reached an epidemic scale, especially in industrialized countries. Such a situation has prompted complex studies in medicinal... (Review)
Review
Oncological diseases have currently reached an epidemic scale, especially in industrialized countries. Such a situation has prompted complex studies in medicinal chemistry focused on the research and development of novel effective anticancer drugs. In this review, the data concerning new 4-thiazolidinone-bearing hybrid molecules with potential anticancer activity reported during the period from the years 2017-2022 are summarized. The main emphasis is on the application of molecular hybridization methodologies and strategies in the design of small molecules as anticancer agents. Based on the analyzed data, it was observed that the main directions in this field are the hybridization of scaffolds, the hybrid-pharmacophore approach, and the analogue-based drug design of 4-thiazolidinone cores with early approved drugs, natural compounds, and privileged heterocyclic scaffolds. The mentioned design approaches are effective tools/sources for the generation of hit/lead compounds with anticancer activity and will be relevant to future studies.
Topics: Thiazolidines; Drug Design; Antineoplastic Agents; Chemistry, Pharmaceutical
PubMed: 36361924
DOI: 10.3390/ijms232113135 -
International Journal of Molecular... Oct 2018Cancer represents a group of heterogeneous diseases characterized by uncontrolledgrowth and spread of abnormal cells, ultimately leading to death. Nanomedicine plays a... (Review)
Review
Cancer represents a group of heterogeneous diseases characterized by uncontrolledgrowth and spread of abnormal cells, ultimately leading to death. Nanomedicine plays a significantrole in the development of nanodrugs, nanodevices, drug delivery systems and nanocarriers. Someof the major issues in the treatment of cancer are multidrug resistance (MDR), narrow therapeuticwindow and undesired side effects of available anticancer drugs and the limitations of anticancerdrugs. Several nanosystems being utilized for detection, diagnosis and treatment such as theranosticcarriers, liposomes, carbon nanotubes, quantum dots, polymeric micelles, dendrimers and metallicnanoparticles. However, nonbiodegradable nanoparticles causes high tissue accumulation andleads to toxicity. MDR is considered a major impediment to cancer treatment due to metastatictumors that develop resistance to chemotherapy. MDR contributes to the failure of chemotherapiesin various cancers, including breast, ovarian, lung, gastrointestinal and hematological malignancies.Moreover, the therapeutic efficiency of anticancer drugs or nanoparticles (NPs) used alone is lessthan that of the combination of NPs and anticancer drugs. Combination therapy has long beenadopted as the standard first-line treatment of several malignancies to improve the clinical outcome.Combination therapy with anticancer drugs has been shown to generally induce synergistic drugactions and deter the onset of drug resistance. Therefore, this review is designed to report andanalyze the recent progress made to address combination therapy using NPs and anticancer drugs.We first provide a comprehensive overview of the angiogenesis and of the different types of NPscurrently used in treatments of cancer; those emphasized in this review are liposomes, polymericNPs, polymeric micelles (PMs), dendrimers, carbon NPs, nanodiamond (ND), fullerenes, carbonnanotubes (CNTs), graphene oxide (GO), GO nanocomposites and metallic NPs used forcombination therapy with various anticancer agents. Nanotechnology has provided the convenienttools for combination therapy. However, for clinical translation, we need continued improvementsin the field of nanotechnology.
Topics: Animals; Antineoplastic Agents; Drug Therapy, Combination; Humans; Nanoparticles
PubMed: 30347840
DOI: 10.3390/ijms19103264 -
Molecules (Basel, Switzerland) Jul 2022Cyclic peptides have been widely reported to have therapeutic abilities in the treatment of cancer. This has been proven through in vitro and in vivo studies against... (Review)
Review
Cyclic peptides have been widely reported to have therapeutic abilities in the treatment of cancer. This has been proven through in vitro and in vivo studies against breast, lung, liver, colon, and prostate cancers, among others. The multitude of data available in the literature supports the potential of cyclic peptides as anticancer agents. This review summarizes the findings from previously reported studies and discusses the different cyclic peptide compounds, the sources, and their modes of action as anticancer agents. The prospects and future of cyclic peptides will also be described to give an overview on the direction of cyclic peptide development for clinical applications.
Topics: Antineoplastic Agents; Humans; Neoplasms; Peptides; Peptides, Cyclic
PubMed: 35889301
DOI: 10.3390/molecules27144428